Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.

Ciurea, Adrian; Papagiannoulis, Eleftherios; Bürki, Kristina; von Loga, Isabell; Micheroli, Raphael; Möller, Burkhard; Rubbert-Roth, Andrea; Andor, Michael; Bräm, René; Müller, Angela; Dan, Diana; Kyburz, Diego; Distler, Oliver; Scherer, Almut; Finckh, Axel (2021). Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Annals of the rheumatic diseases, 80(2), pp. 238-241. BMJ Publishing Group 10.1136/annrheumdis-2020-218705

[img] Text
Impact of Covid_Möller_2020.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (540kB) | Request a copy

OBJECTIVES

To investigate whether the transient reduction in rheumatology services imposed by virus containment measures during the COVID-19 pandemic was associated with disease worsening in axial spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA).

METHODS

Patient-reported disease activity assessed during face-to-face visits and/or via a smartphone application were compared between three periods of each 2 months duration (before, during and after the COVID-19-wave) from January to June 2020 in 666 patients with axSpA, RA and PsA in the Swiss Clinical Quality Management cohort.

RESULTS

The number of consultations dropped by 52%, whereas the number of remote assessments increased by 129%. The proportion of patients with drug non-compliance slightly increased during the pandemic, the difference reaching statistical significance in axSpA (19.9% vs 13.2% before the pandemic, p=0.003). The proportion of patients with disease flares remained stable (<15%). There was no increase in mean values of the Bath Ankylosing Disease Activity Index, the Rheumatoid Arthritis Disease Activity Index-5 and the Patient Global Assessment in patients with axSpA, RA and PsA, respectively.

CONCLUSION

A short interruption of in-person patient-rheumatologist interactions had no major detrimental impact on the disease course of axSpA, RA and PsA as assessed by patient-reported outcomes.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Möller, Burkhard

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0003-4967

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Marlise Bühler Zimmermann

Date Deposited:

11 Nov 2020 15:59

Last Modified:

15 Jan 2021 01:32

Publisher DOI:

10.1136/annrheumdis-2020-218705

PubMed ID:

32963052

Uncontrolled Keywords:

ankylosing arthritis epidemiology psoriatic rheumatoid spondylitis

BORIS DOI:

10.7892/boris.148060

URI:

https://boris.unibe.ch/id/eprint/148060

Actions (login required)

Edit item Edit item
Provide Feedback